Answers are grounded in this paper and cite their sources.
Programmed cell death protein-1 (PD-1) inhibitor-based therapy has demonstrated promising results in metastatic gastric cancer (MGC). However, the previous researches are mostly clinical trials and have reached various conclusions. Our objective is to investigate the efficacy of PD-1 inhibitor-based treatment as first-line therapy for MGC, utilizing real-world data from China, and further analyze predictive biomarkers for efficacy.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: